Bionano Genomics (BNGO) Stock Forecast, Price Target & Predictions
BNGO Stock Forecast
Bionano Genomics stock forecast is as follows: an average price target of $59.33 (represents a 13691.26% upside from BNGO’s last price of $0.43) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
BNGO Price Target
The average price target for Bionano Genomics (BNGO) is $59.33 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $175.00 to $1.00. This represents a potential 13691.26% upside from BNGO's last price of $0.43.
BNGO Analyst Ratings
According to 5 Wall Street analysts, Bionano Genomics's rating consensus is 'Buy'. The analyst rating breakdown for BNGO stock is 0 'Strong Buy' (0.00%), 3 'Buy' (60.00%), 2 'Hold' (40.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Bionano Genomics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 28, 2024 | Sung Ji Nam | Scotiabank | $1.00 | $0.51 | 95.08% | 132.45% |
| May 16, 2024 | Mark Massaro | BTIG | $2.00 | $1.15 | 73.91% | 364.90% |
| May 25, 2023 | Bionano Genomics's | EF Hutton | $175.00 | $65.00 | 169.23% | 40578.75% |
| Dec 12, 2022 | - | BTIG | $350.00 | $219.00 | 59.82% | 81257.51% |
The latest Bionano Genomics stock forecast, released on Aug 28, 2024 by Sung Ji Nam from Scotiabank, set a price target of $1.00, which represents a 95.08% increase from the stock price at the time of the forecast ($0.51), and a 132.45% increase from BNGO last price ($0.43).
Bionano Genomics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 2 |
| Avg Price Target | $1.00 | $1.00 | $1.50 |
| Last Closing Price | $0.43 | $0.43 | $0.43 |
| Upside/Downside | 132.45% | 132.45% | 248.68% |
In the current month, the average price target of Bionano Genomics stock is $1.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 132.45% increase as opposed to Bionano Genomics's last price of $0.43. This month's average price target is down 0.00% compared to last quarter, and down -33.33% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 10, 2024 | BTIG | Buy | Neutral | Downgrade |
| Aug 28, 2024 | Scotiabank | Sector Outperform | Sector Perform | Downgrade |
| May 16, 2024 | BTIG | Buy | Buy | Hold |
| May 25, 2023 | EF Hutton | - | Buy | Initialise |
| Jan 05, 2023 | Scotiabank | - | Sector Outperform | Initialise |
| Jan 25, 2021 | Odeon Capital Group LLC | Buy | Buy | Hold |
| Jan 16, 2021 | Oppenheimer | Buy | Buy | Hold |
| Dec 30, 2020 | Oppenheimer | Outperform | Outperform | Hold |
Bionano Genomics's last stock rating was published by BTIG on Sep 10, 2024. The company Downgrade its BNGO rating from "Buy" to "Neutral".
Bionano Genomics Financial Forecast
Bionano Genomics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $9.32M | $8.66M | $7.42M | $8.21M | $7.22M | $6.67M | $5.70M | $6.30M | $4.66M | $3.86M | $3.17M | $3.99M | $2.20M | $1.18M | $1.14M | $2.79M | $3.31M |
| Avg Forecast | $16.74M | $14.69M | $13.40M | $12.43M | $13.12M | $11.48M | $10.65M | $9.79M | $11.76M | $8.21M | $8.02M | $8.48M | $10.55M | $9.08M | $8.29M | $7.21M | $8.09M | $6.79M | $6.28M | $5.70M | $5.57M | $4.22M | $3.50M | $2.97M | $3.50M | $2.07M | $863.00K | $1.70M | $4.42M | $4.03M |
| High Forecast | $18.15M | $15.92M | $14.53M | $13.48M | $14.22M | $12.45M | $11.54M | $10.62M | $12.75M | $8.90M | $8.69M | $9.19M | $10.94M | $9.84M | $8.99M | $7.82M | $8.78M | $7.37M | $6.87M | $6.23M | $6.09M | $4.61M | $3.83M | $3.25M | $3.82M | $2.26M | $943.12K | $1.86M | $4.83M | $4.40M |
| Low Forecast | $14.48M | $12.70M | $11.59M | $10.75M | $11.35M | $9.93M | $9.21M | $8.47M | $10.17M | $7.10M | $6.93M | $7.33M | $9.94M | $7.85M | $7.17M | $6.24M | $7.00M | $5.88M | $5.94M | $5.39M | $5.27M | $3.99M | $3.31M | $2.81M | $3.31M | $1.95M | $815.70K | $1.61M | $4.18M | $3.81M |
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 1 | - | - | - | - | - | - | - | - | - | 10 | 10 | 10 | 10 | 10 | 9 | 9 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.03% | 1.04% | 1.03% | 1.01% | 1.06% | 1.06% | 1.00% | 1.13% | 1.10% | 1.10% | 1.07% | 1.14% | 1.06% | 1.37% | 0.67% | 0.63% | 0.82% |
Bionano Genomics's average Quarter revenue forecast for Dec 23 based on 4 analysts is $10.55M, with a low forecast of $9.94M, and a high forecast of $10.94M. BNGO's average Quarter revenue forecast represents a 13.25% increase compared to the company's last Quarter revenue of $9.32M (Sep 23).
Bionano Genomics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 1 | - | - | - | - | - | - | - | - | - | 10 | 10 | 10 | 10 | 10 | 9 | 9 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-31.50M | $-39.24M | $-37.02M | $-36.80M | $-29.28M | $-29.69M | $-27.63M | $-17.10M | $-20.19M | $-18.05M | $-8.96M | $-10.56M | $-9.86M | $-7.21M | $-9.45M | $-6.71M | $-5.54M |
| Avg Forecast | $-16.74M | $-14.69M | $-13.40M | $-12.43M | $-13.12M | $-11.48M | $-10.65M | $-9.79M | $-11.76M | $-8.21M | $-8.02M | $-8.48M | $-10.55M | $-9.08M | $-8.29M | $-7.21M | $-8.09M | $-21.29M | $-6.28M | $-14.09M | $-5.57M | $-4.22M | $-3.50M | $-8.96M | $-3.50M | $-2.07M | $-7.21M | $-1.70M | $-4.42M | $-4.03M |
| High Forecast | $-14.48M | $-12.70M | $-11.59M | $-10.75M | $-11.35M | $-9.93M | $-9.21M | $-8.47M | $-10.17M | $-7.10M | $-6.93M | $-7.33M | $-9.94M | $-7.85M | $-7.17M | $-6.24M | $-7.00M | $-17.03M | $-5.94M | $-11.27M | $-5.27M | $-3.99M | $-3.31M | $-7.16M | $-3.31M | $-1.95M | $-5.77M | $-1.61M | $-4.18M | $-3.81M |
| Low Forecast | $-18.15M | $-15.92M | $-14.53M | $-13.48M | $-14.22M | $-12.45M | $-11.54M | $-10.62M | $-12.75M | $-8.90M | $-8.69M | $-9.19M | $-10.94M | $-9.84M | $-8.99M | $-7.82M | $-8.78M | $-25.54M | $-6.87M | $-16.91M | $-6.09M | $-4.61M | $-3.83M | $-10.75M | $-3.82M | $-2.26M | $-8.66M | $-1.86M | $-4.83M | $-4.40M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.47% | 4.73% | 5.13% | 4.55% | 1.38% | 4.73% | 1.96% | 3.07% | 4.78% | 5.15% | 1.00% | 3.02% | 4.77% | 1.00% | 5.55% | 1.52% | 1.37% |
undefined analysts predict BNGO's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Bionano Genomics's previous annual EBITDA (undefined) of $NaN.
Bionano Genomics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 1 | - | - | - | - | - | - | - | - | - | 10 | 10 | 10 | 10 | 10 | 9 | 9 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-112.57M | $-38.91M | $-37.12M | $-38.68M | $-31.81M | $-32.16M | $-29.95M | $-34.38M | $-20.75M | $-18.79M | $-9.95M | $-11.73M | $-10.79M | $-8.07M | $-10.51M | $-7.90M | $-6.40M |
| Avg Forecast | $-7.77M | $-7.77M | $-9.46M | $-11.49M | $-9.87M | $-10.29M | $-11.35M | $-13.21M | $-12.14M | $-13.85M | $-28.07M | $-43.53M | $-58.84M | $-65.53M | $-70.46M | $-70.65M | $-75.97M | $-21.88M | $-60.82M | $-14.12M | $-44.25M | $-38.91M | $-30.41M | $-9.95M | $-35.48M | $-35.48M | $-8.07M | $-145.30M | $-121.65M | $-405.50M |
| High Forecast | $-6.41M | $-6.41M | $-7.80M | $-9.47M | $-8.14M | $-8.48M | $-9.35M | $-10.89M | $-10.01M | $-9.45M | $-23.13M | $-35.88M | $-50.73M | $-54.01M | $-58.07M | $-58.23M | $-62.61M | $-17.50M | $-56.49M | $-11.30M | $-41.10M | $-36.14M | $-28.25M | $-7.96M | $-32.95M | $-32.95M | $-6.46M | $-134.95M | $-112.98M | $-376.60M |
| Low Forecast | $-8.62M | $-8.62M | $-10.50M | $-12.74M | $-10.95M | $-11.41M | $-12.58M | $-14.66M | $-13.47M | $-19.52M | $-31.13M | $-48.29M | $-68.31M | $-72.69M | $-78.15M | $-78.37M | $-84.27M | $-26.25M | $-68.17M | $-16.94M | $-49.59M | $-43.61M | $-34.08M | $-11.94M | $-39.76M | $-39.76M | $-9.69M | $-162.84M | $-136.33M | $-454.44M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.72% | 0.55% | 0.53% | 0.51% | 1.45% | 0.53% | 2.12% | 0.78% | 0.53% | 0.62% | 1.00% | 0.33% | 0.30% | 1.00% | 0.07% | 0.06% | 0.02% |
Bionano Genomics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. BNGO's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Bionano Genomics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 1 | - | - | - | - | - | - | - | - | - | 10 | 10 | 10 | 10 | 10 | 9 | 9 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $24.90M | $26.94M | $25.98M | $25.32M | $21.22M | $21.78M | $20.28M | $19.81M | $15.33M | $13.83M | $9.53M | $9.43M | $8.66M | $5.61M | $7.37M | $5.86M | $4.45M |
| Avg Forecast | $49.27M | $43.23M | $39.43M | $36.58M | $38.61M | $33.79M | $31.33M | $28.82M | $34.60M | $24.15M | $23.60M | $24.96M | $31.05M | $26.72M | $24.40M | $21.23M | $23.82M | $19.99M | $18.49M | $16.78M | $16.40M | $12.42M | $10.31M | $8.74M | $10.29M | $6.08M | $2.54M | $5.01M | $13.01M | $11.86M |
| High Forecast | $53.41M | $46.86M | $42.75M | $39.65M | $41.85M | $36.63M | $33.96M | $31.24M | $37.51M | $26.18M | $25.58M | $27.05M | $32.18M | $28.96M | $26.45M | $23.01M | $25.82M | $21.67M | $20.20M | $18.34M | $17.92M | $13.58M | $11.27M | $9.55M | $11.25M | $6.65M | $2.78M | $5.47M | $14.22M | $12.96M |
| Low Forecast | $42.61M | $37.38M | $34.10M | $31.63M | $33.39M | $29.22M | $27.09M | $24.92M | $29.92M | $20.88M | $20.41M | $21.58M | $29.25M | $23.11M | $21.10M | $18.36M | $20.60M | $17.29M | $17.47M | $15.86M | $15.50M | $11.74M | $9.74M | $8.26M | $9.73M | $5.75M | $2.40M | $4.73M | $12.30M | $11.21M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.93% | 1.10% | 1.22% | 1.06% | 1.06% | 1.18% | 1.21% | 1.21% | 1.23% | 1.34% | 1.09% | 0.92% | 1.42% | 2.21% | 1.47% | 0.45% | 0.38% |
Bionano Genomics's average Quarter SG&A projection for Dec 23 is $31.05M, based on 4 Wall Street analysts, with a range of $29.25M to $32.18M. The forecast indicates a 24.72% rise compared to BNGO last annual SG&A of $24.90M (Sep 23).
Bionano Genomics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 1 | - | - | - | - | - | - | - | - | - | 10 | 10 | 10 | 10 | 10 | 9 | 9 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-3.22 | $-1.24 | $-0.12 | $-0.13 | $-0.11 | $-0.11 | $-0.11 | $-0.12 | $-0.07 | $-0.07 | $-0.04 | $-0.06 | $-0.08 | $-0.09 | $-0.30 | $-0.23 | $-0.59 |
| Avg Forecast | $-0.12 | $-0.12 | $-0.14 | $-0.17 | $-0.15 | $-0.15 | $-0.17 | $-0.20 | $-0.18 | $-0.20 | $-0.42 | $-0.64 | $-0.87 | $-0.97 | $-1.04 | $-1.05 | $-1.12 | $-1.13 | $-0.90 | $-0.75 | $-0.65 | $-0.58 | $-0.45 | $-0.45 | $-0.53 | $-0.53 | $-0.87 | $-2.15 | $-1.80 | $-6.00 |
| High Forecast | $-0.09 | $-0.09 | $-0.12 | $-0.14 | $-0.12 | $-0.13 | $-0.14 | $-0.16 | $-0.15 | $-0.14 | $-0.34 | $-0.53 | $-0.75 | $-0.80 | $-0.86 | $-0.86 | $-0.93 | $-0.93 | $-0.84 | $-0.69 | $-0.61 | $-0.53 | $-0.42 | $-0.42 | $-0.49 | $-0.49 | $-0.80 | $-2.00 | $-1.67 | $-5.57 |
| Low Forecast | $-0.13 | $-0.13 | $-0.16 | $-0.19 | $-0.16 | $-0.17 | $-0.19 | $-0.22 | $-0.20 | $-0.29 | $-0.46 | $-0.71 | $-1.01 | $-1.08 | $-1.16 | $-1.16 | $-1.25 | $-1.26 | $-1.01 | $-0.84 | $-0.73 | $-0.65 | $-0.50 | $-0.50 | $-0.59 | $-0.59 | $-0.97 | $-2.41 | $-2.02 | $-6.72 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.32% | 1.19% | 0.11% | 0.12% | 0.10% | 0.12% | 0.15% | 0.18% | 0.12% | 0.16% | 0.09% | 0.12% | 0.15% | 0.10% | 0.14% | 0.13% | 0.10% |
According to undefined Wall Street analysts, Bionano Genomics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to BNGO previous annual EPS of $NaN (undefined).
Bionano Genomics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BNGO | Bionano Genomics | $0.43 | $59.33 | 13697.67% | Buy |
| STAA | STAAR Surgical Company | $32.38 | $54.58 | 68.56% | Buy |
| NVST | Envista | $19.41 | $23.83 | 22.77% | Hold |
| BDX | Becton, Dickinson and Company | $234.18 | $280.55 | 19.80% | Buy |
| WST | West Pharmaceutical Services | $300.67 | $345.33 | 14.85% | Buy |
| RMD | ResMed | $248.93 | $209.33 | -15.91% | Hold |
| ISRG | Intuitive Surgical | $489.86 | $393.85 | -19.60% | Buy |
BNGO Forecast FAQ
Is Bionano Genomics a good buy?
Yes, according to 5 Wall Street analysts, Bionano Genomics (BNGO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 60.00% of BNGO's total ratings.
What is BNGO's price target?
Bionano Genomics (BNGO) average price target is $59.33 with a range of $1 to $175, implying a 13691.26% from its last price of $0.43. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Bionano Genomics stock go up soon?
According to Wall Street analysts' prediction for BNGO stock, the company can go up by 13691.26% (from the last price of $0.43 to the average price target of $59.33), up by 40578.75% based on the highest stock price target, and up by 132.45% based on the lowest stock price target.
Can Bionano Genomics stock reach $1?
BNGO's average twelve months analyst stock price target of $59.33 supports the claim that Bionano Genomics can reach $1 in the near future.
What is Bionano Genomics's current price target trend?
1 Wall Street analyst forecast a $1 price target for Bionano Genomics (BNGO) this month, up 132.45% from its last price of $0.43. Compared to the last 3 and 12 months, the average price target increased by 132.45% and increased by 248.68%, respectively.
What are Bionano Genomics's analysts' financial forecasts?
Bionano Genomics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $45.05M (high $48.83M, low $38.96M), average EBITDA is $-45.046M (high $-38.955M, low $-48.831M), average net income is $-44.722M (high $-36.86M, low $-49.607M), average SG&A $132.55M (high $143.69M, low $114.63M), and average EPS is $-0.662 (high $-0.545, low $-0.734). BNGO's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $57.27M (high $62.08M, low $49.52M), average EBITDA is $-57.266M (high $-49.524M, low $-62.079M), average net income is $-36.495M (high $-30.08M, low $-40.482M), average SG&A $168.51M (high $182.67M, low $145.72M), and average EPS is $-0.54 (high $-0.445, low $-0.599).
Did the BNGO's actual financial results beat the analysts' financial forecasts?
Based on Bionano Genomics's last annual report (Dec 2023), the company's revenue was $36.12M, beating the average analysts forecast of $35.14M by 2.78%. Apple's EBITDA was $-215M, beating the average prediction of $-35.141M by 512.53%. The company's net income was $-232M, missing the average estimation of $-265M by -12.43%. Apple's SG&A was $93.5M, missing the average forecast of $103.4M by -9.58%. Lastly, the company's EPS was $-6.81, beating the average prediction of $-3.928 by 73.36%. In terms of the last quarterly report (Sep 2023), Bionano Genomics's revenue was $9.32M, beating the average analysts' forecast of $9.08M by 2.62%. The company's EBITDA was $-31.5M, beating the average prediction of $-9.08M by 246.90%. Bionano Genomics's net income was $-113M, beating the average estimation of $-65.533M by 71.77%. The company's SG&A was $24.9M, missing the average forecast of $26.72M by -6.82%. Lastly, the company's EPS was $-3.22, beating the average prediction of $-0.97 by 232.08%